PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Gupta, Samir
TI  - BMS-986001 is Effective Treatment for HIV-1-Infected Subjects
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 16--17
VI  - 14
IP  - 28
4099  - http://mdc.sagepub.com/content/14/28/16.short
4100  - http://mdc.sagepub.com/content/14/28/16.full
AB  - BMS-986001 is a novel nucleoside analog reverse-transcriptase inhibitor that, in higher doses, demonstrated comparable efficacy to tenofovir in treatment-naïve HIV-1-infected subjects. This article presents the results of this phase 2b randomized dose trial (active controlled, blinded to BMS-986001) with worldwide recruitment.